Group 1 - The core point of the news is that southbound funds have been reducing their holdings in Qiming Medical-B (02500.HK), with a total net reduction of 97,000 shares over the last five trading days and 753,500 shares over the last twenty trading days [1][2] - As of February 5, 2026, southbound funds hold 52,175,600 shares of Qiming Medical-B, which accounts for 11.82% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show a consistent trend of reduction, with a decrease of 22,000 shares on February 5, 2026, and smaller reductions on previous trading days [2] Group 2 - Qiming Medical Co., Ltd. specializes in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices for treating heart valve diseases [2] - The company's product line includes devices for aortic, pulmonary, mitral, and tricuspid valve interventions, as well as systems for treating hypertrophic cardiomyopathy and renal denervation [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, and TriGUARD3 embolic protection device [2]
启明医疗-B（02500.HK）：2月5日南向资金减持2.2万股